EP3347012A4 - Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems - Google Patents

Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems Download PDF

Info

Publication number
EP3347012A4
EP3347012A4 EP16845102.9A EP16845102A EP3347012A4 EP 3347012 A4 EP3347012 A4 EP 3347012A4 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A4 EP3347012 A4 EP 3347012A4
Authority
EP
European Patent Office
Prior art keywords
muscarinic
combinations
controlling
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16845102.9A
Other languages
English (en)
French (fr)
Other versions
EP3347012A1 (de
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of EP3347012A1 publication Critical patent/EP3347012A1/de
Publication of EP3347012A4 publication Critical patent/EP3347012A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16845102.9A 2015-09-11 2016-09-09 Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems Withdrawn EP3347012A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217081P 2015-09-11 2015-09-11
US201662351382P 2016-06-17 2016-06-17
PCT/US2016/050907 WO2017044714A1 (en) 2015-09-11 2016-09-09 Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system

Publications (2)

Publication Number Publication Date
EP3347012A1 EP3347012A1 (de) 2018-07-18
EP3347012A4 true EP3347012A4 (de) 2019-04-17

Family

ID=58240063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845102.9A Withdrawn EP3347012A4 (de) 2015-09-11 2016-09-09 Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems

Country Status (3)

Country Link
EP (1) EP3347012A4 (de)
CA (1) CA2996719A1 (de)
WO (1) WO2017044714A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061821B1 (de) 2009-07-22 2019-07-10 Puretech Health LLC Zusammensetzungen zur behandlung von durch muscarinrezeptoraktivierung gelinderten leiden
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
IL281809B (en) 2018-09-28 2022-09-01 Karuna Therapeutics Inc Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144749A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2016144719A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
KR20200065113A (ko) * 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144749A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2016144719A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017044714A1 *
SRAMEK J J ET AL: "THE SAFETY AND TOLERANCE OF XANOMELINE TARTRATE IN PATIENTS WITH ALZHEIMER'S DISEASE", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 35, 1 January 1995 (1995-01-01), pages 800 - 806, XP000563129, ISSN: 0091-2700 *

Also Published As

Publication number Publication date
CA2996719A1 (en) 2017-03-16
WO2017044714A1 (en) 2017-03-16
EP3347012A1 (de) 2018-07-18

Similar Documents

Publication Publication Date Title
IL279931A (en) Gene therapies for lysosomal disorders
EP3692075A4 (de) Gentherapien für lysosomale erkrankungen
EP3364993A4 (de) Verfahren zur behandlung des angelman-syndroms und verwandter störungen
EP3692151A4 (de) Gentherapien für lyosomale erkrankungen
IL266692A (en) Methods and systems for predicting DNA accessibility in a cancer genome
EP3104708A4 (de) Regenerative zelltherapie für erkrankungen des zentralen nervensystems (zns) und ptsd
EP3551052A4 (de) Verfahren und systeme zur identifizierung von hirnerkrankungen
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
MA51074A (fr) Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
ZA201806382B (en) Liquid filter arrangement and methods
EP2807412A4 (de) Nervenüberwachungsverfahren und systeme zur behandlung von erkrankungen des rachens
HUE051488T2 (hu) Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
FR2997317B1 (fr) Adsorbant de tamis moleculaire de 5 a et procede pour la preparation de celui-ci
EP3162567A4 (de) Kanalelement, flüssigkeitsausstosskopf und aufzeichnungsvorrichtung
EP3442547A4 (de) Probiotische therapien für entwicklungsstörungen und andere neurologische erkrankungen
EP3618824A4 (de) Verwendung von n-acetylcystein zur behandlung von erkrankungen des zentralen nervensystems
IL233141B (en) A pharmaceutical preparation for the treatment of hearing and balance disorders
EP2934565A4 (de) Ghrh-agonisten zur behandlung von ischämischen erkrankungen
EP3199353A4 (de) Flüssigkeitsausstosskopf und aufzeichnungsvorrichtung
HUE057479T2 (hu) Szûrõkészülék elválasztólappal
EP3318408A4 (de) Flüssigkeitsentladungskopf und aufzeichnungsvorrichtung mit verwendung davon
EP3463417A4 (de) Kombinationstherapien zur regeneration/zum austausch von sensorischem haarzellen im innenohr
EP2893014A4 (de) Transponierbare elemente, tdp-43 und neurodegenerative erkrankungen
EP3347011A4 (de) Muscarinkombination und deren verwendung zur bekämpfung von hypocholinergen störungen des zentralen nervensystems
EP3395581A4 (de) Flüssigkeitsausstossvorrichtung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031435000

Ipc: A61K0031216000

A4 Supplementary search report drawn up and despatched

Effective date: 20190318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/454 20060101ALI20190312BHEP

Ipc: A61K 45/06 20060101ALI20190312BHEP

Ipc: A61K 31/216 20060101AFI20190312BHEP

Ipc: A61K 31/517 20060101ALI20190312BHEP

Ipc: A61K 31/4439 20060101ALI20190312BHEP

Ipc: A61K 31/4178 20060101ALI20190312BHEP

Ipc: A61K 9/70 20060101ALI20190312BHEP

Ipc: A61P 25/24 20060101ALI20190312BHEP

Ipc: A61K 31/166 20060101ALI20190312BHEP

Ipc: A61P 25/28 20060101ALI20190312BHEP

Ipc: A61P 25/18 20060101ALI20190312BHEP

Ipc: A61P 25/00 20060101ALI20190312BHEP

Ipc: A61P 25/14 20060101ALI20190312BHEP

Ipc: A61K 31/439 20060101ALI20190312BHEP

Ipc: A61P 43/00 20060101ALI20190312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200623

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230310